For HCPs Only
Recent Clinical Updates
Loading latest clinical updates

Clinical Intelligence & Drug Records for US-Licensed Practitioners

The integrated, institutional-grade registry trusted by US-licensed practitioners for evidence-based clinical data, drug information, and peer-reviewed drug updates.

Drug Update Briefing

Weekly drug approvals, safety updates, and specialty coverage for healthcare professionals.

Clinical Resources

Drug updates, reference data, and specialist-led coverage.

Recent Clinical Updates

Latest Drug & Specialty Updates

View All

Specialty Coverage

Therapeutic-area updates for clinical review.

All Specialties

Drug Information

FDA drug records and prescribing context.

Review drug records, NDC references, dosage tools, and interaction resources alongside clinical coverage.

FDA data

Drug Reference

Drug approvals, labels, and clinical context.

Access structured FDA label data, dosage references, NDC records, interactions, and prescribing context.

Clinical Coverage

Additional Drug Updates

Infectious Disease

FDA Reviews Ensitrelvir for COVID-19 Post-Exposure Prevention: First Oral Antiviral in 2026

3h ago|3 min read|By Dr. Simran Kohli
Endocrinology

FDA Approves Afrezza for Pediatric Use: First Inhaled Insulin for Type 1 and Type 2 Diabetes in Children

3h ago|3 min read|By Dr. Amit Desai
Neurology

FDA Approves Wellcovorin for Cerebral Folate Transport Deficiency: First Treatment Available

3h ago|3 min read|By Dr. Vikram Patel
Dermatology

Difamilast vs Crisaborole: Topical PDE4 Inhibitors for Atopic Dermatitis in Pediatrics and Adults

3h ago|3 min read|By Dr. Divya Agarwal
Pulmonology

FDA Approves Depemokimab for Severe Asthma: New Eosinophilic Treatment Option

May 3|3 min read|By Dr. Nikhil Chatterjee
Dermatology

IL-17 vs IL-23 vs TNF Inhibitors: 2025 Comparison for Plaque Psoriasis Treatment

May 3|3 min read|By Dr. Rohan Gupta
Endocrinology

Semaglutide: Key Differences Between Ozempic and Wegovy for Diabetes and Weight Loss

May 3|3 min read|By Dr. Amit Desai
Endocrinology

FDA Approves Orforglipron for Chronic Weight Management in Adults with Obesity

May 3|3 min read|By Dr. Amit Desai
Rare Disease

FDA Approves Doxecitine and Doxribtimine for Thymidine Kinase 2 Deficiency: Over 90% Survival Benefit

May 3|3 min read|By Editorial Team
Rare Disease

FDA Approves Yuviwel (navepegritide) for Achondroplasia: Weekly Injection to Enhance Growth in Pediatric Patients

May 3|3 min read|By Editorial Team
Dermatology

FDA Approves Icotrokinra for Plaque Psoriasis: First Oral IL-23 Antagonist

May 3|3 min read|By Dr. Rohan Gupta
Rare Disease

FDA Approves Tividenofusp Alfa for Hunter Syndrome: Neurologic Manifestations Treatment

May 3|3 min read|By Editorial Team
Endocrinology

FDA Approves Insulin Icodec for Type 2 Diabetes: First Once-Weekly Insulin

May 3|3 min read|By Dr. Amit Desai
Dermatology

FDA Approves Icotrokinra for Moderate to Severe Plaque Psoriasis: Oral IL-23 Antagonist for Patients 12 and Older

May 3|3 min read|By Dr. Divya Agarwal
Neurology

FDA Approves Leucovorin for Cerebral Folate Transport Deficiency: First Treatment Available

May 3|3 min read|By Dr. Aditi Kulkarni
Cardiology

FDA Approves Semaglutide for PAD: Improved Functional Outcomes in STRIDE Trial

May 3|3 min read|By Dr. Kavya Sharma
Rare Disease

FDA Approves Navepegritide for Achondroplasia: Weekly Dosing Compared to Voxzogo

May 3|3 min read|By Editorial Team
Endocrinology

FDA Expands Afrezza Label: Inhaled Insulin Approved for Type 1 and Type 2 Diabetes in Children and Adolescents

May 3|3 min read|By Dr. Amit Desai
Infectious Disease

WHO Updates Guidelines for Long COVID Management: Key Strategies for Primary Care

May 2|3 min read|By Dr. Simran Kohli
Dermatology

FDA Approves Icotyde for Moderate to Severe Plaque Psoriasis: New Oral IL-23 Antagonist

May 2|3 min read|By Dr. Rohan Gupta
Pediatrics

FDA Approves Nirsevimab for RSV Prevention in Infants: MELODY Trial

May 2|3 min read|By Dr. Aditya Kumar
Cardiology

FDA Approves Empagliflozin for HFpEF: 21% Reduction in CV Events

May 2|3 min read|By Dr. Arjun Sharma
Oncology

FDA Approves Pembrolizumab for High-Risk Early-Stage TNBC: 63% pCR in KEYNOTE-522

May 2|3 min read|By Dr. Rahul Verma